Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder

Am J Addict. 2025 Jul;34(4):465-469. doi: 10.1111/ajad.70015. Epub 2025 Feb 28.

Abstract

Background/objectives: The pharmacology of fentanyl and xylazine is not characterized in persons regularly exposed to illicit fentanyl. This case series presents individual-level urine pharmacokinetics of fentanyl, norfentanyl, and xylazine in persons with opioid use disorder (OUD).

Methods: Participants (N = 11) provided urine samples (n = 95) for quantitative analysis. Terminal half-lives and predicted detection times were calculated.

Results: Urinary half-life ranges were: fentanyl 1.5-28.7 h, norfentanyl 5.2-27.4 h, and xylazine 1.1-25.2 h. Predicted detection window ranges were: fentanyl 13.0-130.9 h (0.5-5.5 days), norfentanyl 64.8-255.9 h (2.7-10.7 days), and xylazine 13.8-123.4 h (0.6-5.1 days).

Discussion/conclusions: Persons are presenting with a high magnitude of drug exposure that lends to an extended duration of urinary detection.

Significance: First characterization of urinary excretion in persons with OUD.

MeSH terms

  • Adult
  • Analgesics, Opioid* / pharmacokinetics
  • Analgesics, Opioid* / urine
  • Female
  • Fentanyl* / analogs & derivatives
  • Fentanyl* / analogs & derivatives
  • Fentanyl* / pharmacokinetics
  • Fentanyl* / urine
  • Half-Life
  • Humans
  • Male
  • Middle Aged
  • Opioid-Related Disorders* / urine
  • Substance Abuse Detection
  • Xylazine* / pharmacokinetics
  • Xylazine* / urine

Substances

  • Analgesics, Opioid
  • Fentanyl
  • norfentanyl
  • Xylazine